S547 including a mouthwash - based protocol containing epigallocatechin gallate and hyaluronic acid. Time - course plots were generated for each scale to visualise the evolution of toxicity and recovery. Patients with T9 were considered complete; others are ongoing. Results: Longitudinal profiles showed a progressive increase in OMAS and CTCAE from T0 to T6, with partial improvement at T9. MDADI decreased during treatment and improved post - therapy, mirroring functional recovery. The distribution of mucositis severity concentrated in non - severe categories across the cohort; this pattern is coherent with adoption of a mouthwash - based protocol aimed at mitigating peak mucosal injury. The concordant behaviour across objective, clinician - graded, and patient - reported measures supports a robust time - dependent toxicity signature. Conclusion: During CRT, oral mucositis and swallowing dysfunction peak at treatment completion and improve thereafter. Routine monitoring with OMAS (objective lesions), CTCAE (clinical severity), and MDADI (functional impact) provides complementary, clinically actionable information for supportive care. The mouthwash - based supportive protocol aligns with the predominance of mild - to - moderate mucositis and may contribute to limiting peak severity without apparent interference with oncologic therapy. These data endorse integrated clinical–functional assessment and standardised supportive strategies in practice and
Clinical – Head & neck
ESTRO 2026
Digital Poster 709 Comparative analysis of OMAS, MDADI, and CTCAE during concomitant chemoradiotherapy in patients with head and neck cancer at peak mucositis Bianca Santo 1 , Matteo Romanello 2 , Elisa Cavalera 1 , Paola De Franco 1 , Donatella Russo 1 , Maria Cristina Barba 1 , Elisa Ciurlia 1 , Sara De Matteis 1 , Giuseppe Di Paola 1 , Angela Leone 1 , Antonella Papaleo 1 , Antonio Palumbo 2 , Angela Sardaro 1 1 Radiotherapy, "Vito Fazzi" Hospital, Lecce, Italy. 2 Otorhinolaryngology,Head and Neck Surgery, "Vito Fazzi" Hospital, Lecce, Italy Purpose/Objective: Oral mucositis is a frequent acute toxicity during chemoradiotherapy (CRT) for head and neck cancers. OMAS quantifies objective mucosal injury; CTCAE captures clinician - graded severity; MDADI describes patient - reported swallowing function and quality of life. We examined whether these instruments provide overlapping or complementary information at peak toxicity. Material/Methods: Patients were assessed using OMAS, MDADI and CTCAE during concomitant radiotherapy and chemotherapy at time 0, three weeks later and at the end of treatment (T6).Prospectively collected data were analysed at T0, T3, T6, and T9, focusing the comparison on T6 when mucositis typically peaks. Pairwise Pearson correlations were calculated for OMAS–CTCAE, MDADI–CTCAE, and OMAS–MDADI using the harmonised dataset; missing values at T6 were handled by pairwise deletion.
future trials. References:
1.Freites-Martinez A et al Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. 2021 Jan;112(1):90-92.doi: 10.1016/j.ad.2019.05.0092.Minhas S et al Assessment and prevalence of concomitant chemo-radiotherapy- induced oral mucositis in patients with oral squamous cell carcinoma. Turk J Med Sci. 2021 Apr 30;51(2):675- 684. doi: 10.3906/sag-2007-1313.Chen AY et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870- 6 Keywords: epigallocatechin gallate, chemoradiotherapy
Figure
1. Correlation matrix among OMAS, MDADI, and CTCAE at T6.
Results: A total of 31 patients were evaluated in this comparative analysis at the defined timepoints (T0, T3,
Made with FlippingBook - Share PDF online